Minar E, Zazgornik J, Dudczak R, Marosi L
Klin Wochenschr. 1984 Jun 1;62(11):549-53. doi: 10.1007/BF01727750.
In this study we evaluated the effects of an oral combination therapy with cimetidine and pirenzepine on plasma parathyroidhormone (PTH) and calcitonin (CT) levels in 24 patients on maintenance hemodialysis (mean age: 50 years; mean duration of dialysis treatment: 23 months). As compared to the pre-treatment plasma levels of PTH and CT, there were no significant changes of their plasma concentrations during a 4-week administration of 800 mg cimetidine or 100 mg pirenzepine daily, and the concentrations also did not change significantly during the following 4 weeks of combination therapy with cimetidine and pirenzepine in the above mentioned dosage. Serum concentrations of calcium and phosphate and the activity of the alkaline phosphatase showed no significant changes either. Therefore, we suggest that this therapeutic approach cannot be considered for the treatment of uremic hyperparathyroidism.
在本研究中,我们评估了西咪替丁和哌仑西平联合口服疗法对24例维持性血液透析患者(平均年龄:50岁;平均透析治疗时间:23个月)血浆甲状旁腺激素(PTH)和降钙素(CT)水平的影响。与PTH和CT的治疗前血浆水平相比,在每日服用800 mg西咪替丁或100 mg哌仑西平的4周给药期间,其血浆浓度无显著变化,并且在随后4周以上述剂量联合使用西咪替丁和哌仑西平治疗期间,浓度也无显著变化。血清钙、磷浓度及碱性磷酸酶活性也无显著变化。因此,我们认为这种治疗方法不能用于治疗尿毒症性甲状旁腺功能亢进。